Home » Acorda Reports Negative Top Line Results of Study Exploring Ampyra 5mg Efficacy
Acorda Reports Negative Top Line Results of Study Exploring Ampyra 5mg Efficacy
Acorda Therapeutics has reported negative top line results from post-marketing commitment study exploring 5mg dose of Dalfampridine-ER in multiple sclerosis (MS) patients.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May